Evidence map›Paper›PMID 27017198›Full record

ArticleIranian biomedical journal2016

Novel CFTR Mutations in Two Iranian Families with Severe Cystic Fibrosis.

Marzieh Mohseni, Mohammad Razzaghmanesh, Elham Parsi Mehr, Hanieh Zare, Maryam Beheshtian, Hossein Najmabadi

Open access · greenAbstract readCase Reports
In one paragraph

Article in Iranian biomedical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Marzieh MohseniKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
Mohammad RazzaghmaneshKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
Elham Parsi MehrKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
Hanieh ZareKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
Maryam BeheshtianKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
Hossein NajmabadiKariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran.
University of Social Welfare and Rehabilitation Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) is a common autosomal recessive disorder that affects many body systems and is produced by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF is also the most frequently inherited disorder in the West. The aim of this study was to detect the mutations in the CFTR gene in two Iranian families with CF.

methodsAfter DNA extraction using the salting out method, a mutation panel consisting of 35 common mutations was tested by PCR, followed by reverse hybridization Strip Assay. To confirm the mutations, we have also performed Sanger sequencing for all 27 exons, intronic flanking regions, and 5' and 3' UTRs of the CFTR gene.

resultsCarrier testing in a spouse revealed a novel nonsense mutation in the CFTR gene (c.2777 T>A (p.L926X)) in exon 17 for husband and a previously described heterozygous splice site pathogenic mutation (c.1393-1G>A) in his wife. The other novel compound heterozygous missense mutation (c.3119 T>A (p.L1040H)), which was previously reported as nonsense c.3484C>T (p.R1162X) mutation, was found in exon 19 in patient screening.

conclusionTwo novel CFTR mutations in exons 17 and 19 are responsible for CF with severe phenotypes in two Iranian families. These two mutations supplement the mutation spectrum of CFTR and may contribute to a better understanding of CFTR protein function.

Indexed as

Genetic Predisposition to DiseaseAdultBase SequenceChild, PreschoolCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorFemaleGenetic TestingHumansIranMaleMutation, MissenseSequence Analysis, DNACFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisCystic fibrosis transmembrane conductance regulator proteinIranMutationSequence analysis

Identifiers

PMID27017198
PMCPMC4983674
OpenAlexW2320463156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.